SRRD Protein Inhibiting Neurodegenerative Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS are inadequate in addressing protein aggregation, which is a hallmark of these conditions, leading to significant challenges in treatment and disease progression.
Innovation Solution
The use of SRR1 domain-containing protein (SRRD) or its active fragment, which can be delivered to cells via expression constructs or carriers like liposomes or nanoparticles, to reduce protein aggregation by overexpressing the protein or fragment, potentially delaying disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat neurodegenerative diseases, then some symptoms may be managed, but protein aggregation remains unchecked and disease progression continues
Solution Approach 1:
The patent identifies SRRD, a protein that naturally binds to and stabilizes misfolded proteins, converting a potentially harmful aggregation process into a beneficial stabilization mechanism. By leveraging the natural chaperone activity of SRRD, the patent transforms the cell's own protein folding machinery into a therapeutic advantage, where SRRD acts as a molecular chaperone that prevents aggregation of pathogenic proteins like TDP-43 and alpha-synuclein.
Solution Approach 2:
SRRD serves as an intermediary molecule between the cell's protein synthesis machinery and the degradation pathways. It acts as a molecular mediator that binds to misfolded proteins, preventing their aggregation while facilitating their proper folding or targeted degradation, thus serving as a protective intermediate that bridges multiple cellular processes.
2Object-affected harmful factors
If protein aggregation is not properly controlled, then tissue function is impaired, but the underlying mechanisms remain unclear
Solution Approach 1:
The patent demonstrates that SRRD provides self-service protection against protein aggregation through its intrinsic chaperone activity. The protein automatically binds to misfolded proteins and facilitates their proper folding or degradation without requiring external intervention or complex regulatory mechanisms, thereby protecting tissue function through a simple, self-active mechanism.
3Object-generated harmful factors
If SRRD is overexpressed in cells, then protein aggregation is reduced, but the delivery mechanism becomes more complex
Solution Approach 1:
The patent employs universal delivery mechanisms such as liposomes and nanoparticles that can transport SRRD across different cell types and tissue barriers. These multi-functional delivery systems can administer SRRD to various targets including neurons, glial cells, and other tissues, providing broad applicability across different neurodegenerative disease models without requiring disease-specific delivery systems.
Data Source
AI summary
The present disclosure is directed to the use of SRR1 domain-containing protein (SRRD) or active fragment thereof to reduce protein aggregation, such as that occurring in neurodegenerative diseases.